B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18

Benzinga Newsdesk www.benzinga.com Positive 73.5%

Neg 0% Neu 0% Pos 73.5%

B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.